Rockwell Medical Analyst Ratings
Rockwell Medical Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 11/15/2023 | 421.33% | HC Wainwright & Co. | → $11 | Reiterates | Buy → Buy |
| 10/05/2023 | 136.97% | Maxim Group | → $5 | Initiates Coverage On | → Buy |
| 10/04/2023 | 421.33% | HC Wainwright & Co. | → $11 | Reiterates | Buy → Buy |
| 09/28/2023 | 421.33% | HC Wainwright & Co. | → $11 | Reiterates | Buy → Buy |
| 08/15/2023 | 421.33% | HC Wainwright & Co. | → $11 | Reiterates | Buy → Buy |
| 07/17/2023 | 421.33% | HC Wainwright & Co. | $9 → $11 | Maintains | Buy |
| 05/30/2023 | 326.54% | HC Wainwright & Co. | $7 → $9 | Maintains | Buy |
| 05/02/2023 | 231.75% | HC Wainwright & Co. | → $7 | Reiterates | → Buy |
| 04/04/2023 | 231.75% | HC Wainwright & Co. | → $7 | Reiterates | → Buy |
| 02/13/2023 | 231.75% | HC Wainwright & Co. | → $7 | Reiterates | → Buy |
| 02/08/2023 | 231.75% | HC Wainwright & Co. | $8 → $7 | Maintains | Buy |
| 08/30/2022 | 279.15% | HC Wainwright & Co. | $3 → $8 | Maintains | Buy |
| 01/18/2022 | 42.18% | HC Wainwright & Co. | $5 → $3 | Maintains | Buy |
| 09/07/2021 | 136.97% | HC Wainwright & Co. | $5.5 → $5 | Maintains | Buy |
| 02/08/2021 | 160.66% | HC Wainwright & Co. | $9 → $5.5 | Maintains | Buy |
| 04/07/2020 | 326.54% | HC Wainwright & Co. | $11 → $9 | Maintains | Buy |
| 11/12/2019 | 184.36% | Piper Sandler | $10 → $6 | Maintains | Overweight |
| 06/25/2019 | 421.33% | Cantor Fitzgerald | → $11 | Initiates Coverage On | → Overweight |
| 06/24/2019 | 373.93% | Piper Sandler | → $10 | Initiates Coverage On | → Overweight |
| 日期 | 上行/下行 | 分析公司 | 目標價格變動 | 評級變動 | 之前/當前的評級 |
|---|---|---|---|---|---|
| 11/15/2023 | 421.33% | HC Wainwright & Co. | → 11 美元 | 重申 | 購買 → 購買 |
| 10/05/2023 | 136.97% | Maxim 集團 | → 5 美元 | 啓動覆蓋範圍開啓 | → 購買 |
| 2023 年 4 月 10 日 | 421.33% | HC Wainwright & Co. | → 11 美元 | 重申 | 購買 → 購買 |
| 09/28/2023 | 421.33% | HC Wainwright & Co. | → 11 美元 | 重申 | 購買 → 購買 |
| 08/15/2023 | 421.33% | HC Wainwright & Co. | → 11 美元 | 重申 | 購買 → 購買 |
| 07/17/2023 | 421.33% | HC Wainwright & Co. | 9 美元 → 11 美元 | 維護 | 買 |
| 05/30/2023 | 326.54% | HC Wainwright & Co. | 7 美元 → 9 美元 | 維護 | 買 |
| 05/02/2023 | 231.75% | HC Wainwright & Co. | → 7 美元 | 重申 | → 購買 |
| 04/04/2023 | 231.75% | HC Wainwright & Co. | → 7 美元 | 重申 | → 購買 |
| 02/13/2023 | 231.75% | HC Wainwright & Co. | → 7 美元 | 重申 | → 購買 |
| 02/08/2023 | 231.75% | HC Wainwright & Co. | 8 美元 → 7 美元 | 維護 | 買 |
| 08/30/2022 | 279.15% | HC Wainwright & Co. | 3 美元 → 8 美元 | 維護 | 買 |
| 01/18/2022 | 42.18% | HC Wainwright & Co. | 5 美元 → 3 美元 | 維護 | 買 |
| 09/07/2021 | 136.97% | HC Wainwright & Co. | 5.5 美元 → 5 美元 | 維護 | 買 |
| 02/08/2021 | 160.66% | HC Wainwright & Co. | 9 美元 → 5.5 美元 | 維護 | 買 |
| 04/07/2020 | 326.54% | HC Wainwright & Co. | 11 美元 → 9 美元 | 維護 | 買 |
| 2019 年 12 月 11 日 | 184.36% | 派珀·桑德勒 | 10 美元 → 6 美元 | 維護 | 超重 |
| 06/25/2019 | 421.33% | 坎託·菲茨傑拉德 | → 11 美元 | 啓動覆蓋範圍開啓 | → 超重 |
| 06/24/2019 | 373.93% | 派珀·桑德勒 | → 10 美元 | 啓動覆蓋範圍開啓 | → 超重 |
What is the target price for Rockwell Medical (RMTI)?
羅克韋爾醫療（RMTI）的目標價格是多少？
The latest price target for Rockwell Medical (NASDAQ: RMTI) was reported by HC Wainwright & Co. on November 15, 2023. The analyst firm set a price target for $11.00 expecting RMTI to rise to within 12 months (a possible 421.33% upside). 11 analyst firms have reported ratings in the last year.
HC Wainwright & Co. 於2023年11月15日公佈了羅克韋爾醫療（納斯達克股票代碼：RMTI）的最新目標股價。該分析公司將目標股價定爲11.00美元，預計RMTI將在12個月內升至12個月內（可能上漲421.33％）。去年有11家分析公司公佈了評級。
What is the most recent analyst rating for Rockwell Medical (RMTI)?
羅克韋爾醫療（RMTI）的最新分析師評級是多少？
The latest analyst rating for Rockwell Medical (NASDAQ: RMTI) was provided by HC Wainwright & Co., and Rockwell Medical reiterated their buy rating.
Rockwell Medical（納斯達克股票代碼：RMTI）的最新分析師評級由HC Wainwright & Co. 提供，羅克韋爾醫療重申了他們的買入評級。
When is the next analyst rating going to be posted or updated for Rockwell Medical (RMTI)?
羅克韋爾醫療（RMTI）的下一個分析師評級何時公佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Rockwell Medical, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Rockwell Medical was filed on November 15, 2023 so you should expect the next rating to be made available sometime around November 15, 2024.
分析師在進行了廣泛的研究後得出了股票評級，其中包括瀏覽公開財務報表，與羅克韋爾醫療公司的高管和客戶交談，以及聽取業績電話會議。大多數分析師每三個月做一次這樣的評級，因此每家公司每年應該獲得4次評級。羅克韋爾醫療的最新評級是在2023年11月15日公佈的，因此您應該預計下一個評級將在2024年11月15日左右公佈。
Is the Analyst Rating Rockwell Medical (RMTI) correct?
分析師對羅克韋爾醫療（RMTI）的評級是否正確？
While ratings are subjective and will change, the latest Rockwell Medical (RMTI) rating was a reiterated with a price target of $0.00 to $11.00. The current price Rockwell Medical (RMTI) is trading at is $2.11, which is within the analyst's predicted range.
儘管評級是主觀的，並且會發生變化，但重申了最新的羅克韋爾醫療（RMTI）評級，目標股價爲0.00美元至11.00美元。羅克韋爾醫療（RMTI）目前的交易價格爲2.11美元，在分析師的預測區間內。